nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Loperamide—Toremifene—breast cancer	0.143	0.486	CrCrCtD
Darifenacin—CYP2D6—breast cancer	0.135	0.538	CbGaD
Darifenacin—CYP3A4—breast cancer	0.116	0.462	CbGaD
Darifenacin—Loperamide—Tamoxifen—breast cancer	0.0895	0.305	CrCrCtD
Darifenacin—Methadone—Tamoxifen—breast cancer	0.0615	0.209	CrCrCtD
Darifenacin—CYP3A4—Exemestane—breast cancer	0.0261	0.103	CbGbCtD
Darifenacin—CYP2D6—Idarubicin—breast cancer	0.0236	0.093	CbGbCtD
Darifenacin—CYP3A4—Letrozole—breast cancer	0.0222	0.0876	CbGbCtD
Darifenacin—CYP3A4—Anastrozole—breast cancer	0.0198	0.0781	CbGbCtD
Darifenacin—CYP3A4—Toremifene—breast cancer	0.0181	0.0714	CbGbCtD
Darifenacin—CYP3A4—Fulvestrant—breast cancer	0.0168	0.0664	CbGbCtD
Darifenacin—CYP3A4—Thiotepa—breast cancer	0.015	0.0592	CbGbCtD
Darifenacin—CYP3A4—Ixabepilone—breast cancer	0.0137	0.0541	CbGbCtD
Darifenacin—CYP3A4—Lapatinib—breast cancer	0.0132	0.0521	CbGbCtD
Darifenacin—CYP2D6—Vinorelbine—breast cancer	0.0115	0.0454	CbGbCtD
Darifenacin—CYP2D6—Tamoxifen—breast cancer	0.0104	0.041	CbGbCtD
Darifenacin—CYP3A4—Raloxifene—breast cancer	0.01	0.0395	CbGbCtD
Darifenacin—CYP3A4—Vinorelbine—breast cancer	0.00732	0.0289	CbGbCtD
Darifenacin—CYP2D6—Vinblastine—breast cancer	0.00709	0.028	CbGbCtD
Darifenacin—CYP3A4—Tamoxifen—breast cancer	0.00661	0.0261	CbGbCtD
Darifenacin—CYP3A4—Mitoxantrone—breast cancer	0.00644	0.0254	CbGbCtD
Darifenacin—CYP3A4—Paclitaxel—breast cancer	0.00514	0.0203	CbGbCtD
Darifenacin—CYP3A4—Irinotecan—breast cancer	0.00507	0.02	CbGbCtD
Darifenacin—CYP3A4—Vinblastine—breast cancer	0.00451	0.0178	CbGbCtD
Darifenacin—CYP2D6—Doxorubicin—breast cancer	0.00436	0.0172	CbGbCtD
Darifenacin—CYP3A4—Docetaxel—breast cancer	0.00372	0.0147	CbGbCtD
Darifenacin—CYP3A4—Doxorubicin—breast cancer	0.00277	0.0109	CbGbCtD
Darifenacin—Clotrimazole—KCNN4—breast cancer	0.00091	0.31	CrCbGaD
Darifenacin—Fexofenadine—SLCO1B1—breast cancer	0.000445	0.152	CrCbGaD
Darifenacin—Clotrimazole—CYP17A1—breast cancer	0.000313	0.107	CrCbGaD
Darifenacin—Trospium—CYP2D6—breast cancer	0.00016	0.0545	CrCbGaD
Darifenacin—Clotrimazole—CYP19A1—breast cancer	0.000159	0.0543	CrCbGaD
Darifenacin—Fexofenadine—CYP2D6—breast cancer	0.000113	0.0385	CrCbGaD
Darifenacin—Methadone—CYP19A1—breast cancer	9.34e-05	0.0319	CrCbGaD
Darifenacin—Clotrimazole—CYP2D6—breast cancer	8.72e-05	0.0298	CrCbGaD
Darifenacin—Fexofenadine—ABCB1—breast cancer	8.06e-05	0.0275	CrCbGaD
Darifenacin—Clotrimazole—CYP3A4—breast cancer	7.48e-05	0.0255	CrCbGaD
Darifenacin—Loperamide—CYP2D6—breast cancer	7.18e-05	0.0245	CrCbGaD
Darifenacin—Fentanyl—CYP3A4—breast cancer	6.4e-05	0.0218	CrCbGaD
Darifenacin—Clotrimazole—ABCB1—breast cancer	6.23e-05	0.0212	CrCbGaD
Darifenacin—Loperamide—CYP3A4—breast cancer	6.16e-05	0.021	CrCbGaD
Darifenacin—Weight increased—Doxorubicin—breast cancer	5.73e-05	0.000374	CcSEcCtD
Darifenacin—Pruritus—Gemcitabine—breast cancer	5.72e-05	0.000374	CcSEcCtD
Darifenacin—Nausea—Thiotepa—breast cancer	5.71e-05	0.000373	CcSEcCtD
Darifenacin—Urethral disorder—Methotrexate—breast cancer	5.71e-05	0.000373	CcSEcCtD
Darifenacin—Infection—Docetaxel—breast cancer	5.7e-05	0.000372	CcSEcCtD
Darifenacin—Sinusitis—Epirubicin—breast cancer	5.7e-05	0.000372	CcSEcCtD
Darifenacin—Diarrhoea—Irinotecan—breast cancer	5.68e-05	0.000371	CcSEcCtD
Darifenacin—Diarrhoea—Mitoxantrone—breast cancer	5.68e-05	0.000371	CcSEcCtD
Darifenacin—Dry mouth—Capecitabine—breast cancer	5.67e-05	0.00037	CcSEcCtD
Darifenacin—Shock—Docetaxel—breast cancer	5.65e-05	0.000369	CcSEcCtD
Darifenacin—Nervous system disorder—Docetaxel—breast cancer	5.63e-05	0.000368	CcSEcCtD
Darifenacin—Pruritus—Fluorouracil—breast cancer	5.63e-05	0.000367	CcSEcCtD
Darifenacin—Infestation NOS—Doxorubicin—breast cancer	5.62e-05	0.000367	CcSEcCtD
Darifenacin—Infestation—Doxorubicin—breast cancer	5.62e-05	0.000367	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—breast cancer	5.61e-05	0.000366	CcSEcCtD
Darifenacin—Confusional state—Capecitabine—breast cancer	5.6e-05	0.000366	CcSEcCtD
Darifenacin—Tachycardia—Docetaxel—breast cancer	5.6e-05	0.000366	CcSEcCtD
Darifenacin—Feeling abnormal—Paclitaxel—breast cancer	5.58e-05	0.000364	CcSEcCtD
Darifenacin—Skin disorder—Docetaxel—breast cancer	5.58e-05	0.000364	CcSEcCtD
Darifenacin—Oedema—Capecitabine—breast cancer	5.56e-05	0.000363	CcSEcCtD
Darifenacin—Gastrointestinal pain—Paclitaxel—breast cancer	5.54e-05	0.000362	CcSEcCtD
Darifenacin—Diarrhoea—Gemcitabine—breast cancer	5.53e-05	0.000361	CcSEcCtD
Darifenacin—Infection—Capecitabine—breast cancer	5.52e-05	0.00036	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—breast cancer	5.51e-05	0.000359	CcSEcCtD
Darifenacin—Dizziness—Irinotecan—breast cancer	5.49e-05	0.000359	CcSEcCtD
Darifenacin—Stomatitis—Doxorubicin—breast cancer	5.48e-05	0.000357	CcSEcCtD
Darifenacin—Shock—Capecitabine—breast cancer	5.47e-05	0.000357	CcSEcCtD
Darifenacin—Rhinitis—Epirubicin—breast cancer	5.46e-05	0.000357	CcSEcCtD
Darifenacin—Urinary tract infection—Doxorubicin—breast cancer	5.46e-05	0.000356	CcSEcCtD
Darifenacin—Nervous system disorder—Capecitabine—breast cancer	5.45e-05	0.000356	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—breast cancer	5.44e-05	0.000355	CcSEcCtD
Darifenacin—Diarrhoea—Fluorouracil—breast cancer	5.44e-05	0.000355	CcSEcCtD
Darifenacin—Tachycardia—Capecitabine—breast cancer	5.42e-05	0.000354	CcSEcCtD
Darifenacin—Pharyngitis—Epirubicin—breast cancer	5.41e-05	0.000353	CcSEcCtD
Darifenacin—Skin disorder—Capecitabine—breast cancer	5.4e-05	0.000352	CcSEcCtD
Darifenacin—Sweating—Doxorubicin—breast cancer	5.39e-05	0.000352	CcSEcCtD
Darifenacin—Urinary tract disorder—Epirubicin—breast cancer	5.38e-05	0.000351	CcSEcCtD
Darifenacin—Hyperhidrosis—Capecitabine—breast cancer	5.37e-05	0.000351	CcSEcCtD
Darifenacin—Oedema peripheral—Epirubicin—breast cancer	5.37e-05	0.000351	CcSEcCtD
Darifenacin—Abdominal pain—Paclitaxel—breast cancer	5.35e-05	0.00035	CcSEcCtD
Darifenacin—Urethral disorder—Epirubicin—breast cancer	5.34e-05	0.000349	CcSEcCtD
Darifenacin—Fentanyl—ABCB1—breast cancer	5.33e-05	0.0182	CrCbGaD
Darifenacin—Angiopathy—Methotrexate—breast cancer	5.28e-05	0.000345	CcSEcCtD
Darifenacin—Vomiting—Irinotecan—breast cancer	5.28e-05	0.000345	CcSEcCtD
Darifenacin—Vomiting—Mitoxantrone—breast cancer	5.28e-05	0.000345	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—breast cancer	5.27e-05	0.000344	CcSEcCtD
Darifenacin—Dizziness—Fluorouracil—breast cancer	5.26e-05	0.000343	CcSEcCtD
Darifenacin—Visual impairment—Epirubicin—breast cancer	5.25e-05	0.000343	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—breast cancer	5.25e-05	0.000343	CcSEcCtD
Darifenacin—Rash—Mitoxantrone—breast cancer	5.24e-05	0.000342	CcSEcCtD
Darifenacin—Rash—Irinotecan—breast cancer	5.24e-05	0.000342	CcSEcCtD
Darifenacin—Dermatitis—Mitoxantrone—breast cancer	5.23e-05	0.000342	CcSEcCtD
Darifenacin—Dermatitis—Irinotecan—breast cancer	5.23e-05	0.000342	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Docetaxel—breast cancer	5.23e-05	0.000341	CcSEcCtD
Darifenacin—Headache—Mitoxantrone—breast cancer	5.2e-05	0.00034	CcSEcCtD
Darifenacin—Headache—Irinotecan—breast cancer	5.2e-05	0.00034	CcSEcCtD
Darifenacin—Insomnia—Docetaxel—breast cancer	5.19e-05	0.000339	CcSEcCtD
Darifenacin—Erythema multiforme—Epirubicin—breast cancer	5.15e-05	0.000336	CcSEcCtD
Darifenacin—Vomiting—Gemcitabine—breast cancer	5.14e-05	0.000336	CcSEcCtD
Darifenacin—Loperamide—ABCB1—breast cancer	5.13e-05	0.0175	CrCbGaD
Darifenacin—Dyspnoea—Docetaxel—breast cancer	5.12e-05	0.000334	CcSEcCtD
Darifenacin—Methadone—CYP2D6—breast cancer	5.11e-05	0.0174	CrCbGaD
Darifenacin—Somnolence—Docetaxel—breast cancer	5.1e-05	0.000333	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—breast cancer	5.1e-05	0.000333	CcSEcCtD
Darifenacin—Rash—Gemcitabine—breast cancer	5.1e-05	0.000333	CcSEcCtD
Darifenacin—Dermatitis—Gemcitabine—breast cancer	5.1e-05	0.000333	CcSEcCtD
Darifenacin—Eye disorder—Epirubicin—breast cancer	5.09e-05	0.000333	CcSEcCtD
Darifenacin—Headache—Gemcitabine—breast cancer	5.07e-05	0.000331	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Capecitabine—breast cancer	5.06e-05	0.000331	CcSEcCtD
Darifenacin—Vomiting—Fluorouracil—breast cancer	5.06e-05	0.00033	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—breast cancer	5.06e-05	0.00033	CcSEcCtD
Darifenacin—Dyspepsia—Docetaxel—breast cancer	5.05e-05	0.00033	CcSEcCtD
Darifenacin—Insomnia—Capecitabine—breast cancer	5.03e-05	0.000328	CcSEcCtD
Darifenacin—Rash—Fluorouracil—breast cancer	5.01e-05	0.000327	CcSEcCtD
Darifenacin—Dermatitis—Fluorouracil—breast cancer	5.01e-05	0.000327	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—breast cancer	5e-05	0.000327	CcSEcCtD
Darifenacin—Hypersensitivity—Paclitaxel—breast cancer	4.99e-05	0.000326	CcSEcCtD
Darifenacin—Headache—Fluorouracil—breast cancer	4.98e-05	0.000325	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—breast cancer	4.98e-05	0.000325	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—breast cancer	4.97e-05	0.000324	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—breast cancer	4.96e-05	0.000324	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Docetaxel—breast cancer	4.96e-05	0.000324	CcSEcCtD
Darifenacin—Dyspnoea—Capecitabine—breast cancer	4.95e-05	0.000323	CcSEcCtD
Darifenacin—Angiopathy—Epirubicin—breast cancer	4.94e-05	0.000323	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—breast cancer	4.94e-05	0.000323	CcSEcCtD
Darifenacin—Nausea—Mitoxantrone—breast cancer	4.93e-05	0.000322	CcSEcCtD
Darifenacin—Nausea—Irinotecan—breast cancer	4.93e-05	0.000322	CcSEcCtD
Darifenacin—Mediastinal disorder—Epirubicin—breast cancer	4.91e-05	0.000321	CcSEcCtD
Darifenacin—Pain—Docetaxel—breast cancer	4.91e-05	0.00032	CcSEcCtD
Darifenacin—Constipation—Docetaxel—breast cancer	4.91e-05	0.00032	CcSEcCtD
Darifenacin—Back pain—Methotrexate—breast cancer	4.9e-05	0.00032	CcSEcCtD
Darifenacin—Dyspepsia—Capecitabine—breast cancer	4.89e-05	0.000319	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—breast cancer	4.86e-05	0.000317	CcSEcCtD
Darifenacin—Asthenia—Paclitaxel—breast cancer	4.86e-05	0.000317	CcSEcCtD
Darifenacin—Nausea—Gemcitabine—breast cancer	4.8e-05	0.000314	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Capecitabine—breast cancer	4.8e-05	0.000313	CcSEcCtD
Darifenacin—Pruritus—Paclitaxel—breast cancer	4.79e-05	0.000313	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—breast cancer	4.78e-05	0.000312	CcSEcCtD
Darifenacin—Mental disorder—Epirubicin—breast cancer	4.77e-05	0.000312	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—breast cancer	4.77e-05	0.000311	CcSEcCtD
Darifenacin—Pain—Capecitabine—breast cancer	4.75e-05	0.00031	CcSEcCtD
Darifenacin—Constipation—Capecitabine—breast cancer	4.75e-05	0.00031	CcSEcCtD
Darifenacin—Feeling abnormal—Docetaxel—breast cancer	4.73e-05	0.000309	CcSEcCtD
Darifenacin—Nausea—Fluorouracil—breast cancer	4.72e-05	0.000308	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—breast cancer	4.71e-05	0.000308	CcSEcCtD
Darifenacin—Gastrointestinal pain—Docetaxel—breast cancer	4.69e-05	0.000306	CcSEcCtD
Darifenacin—Flatulence—Epirubicin—breast cancer	4.67e-05	0.000305	CcSEcCtD
Darifenacin—Dysgeusia—Epirubicin—breast cancer	4.65e-05	0.000303	CcSEcCtD
Darifenacin—Diarrhoea—Paclitaxel—breast cancer	4.63e-05	0.000303	CcSEcCtD
Darifenacin—Back pain—Epirubicin—breast cancer	4.59e-05	0.0003	CcSEcCtD
Darifenacin—Feeling abnormal—Capecitabine—breast cancer	4.58e-05	0.000299	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—breast cancer	4.57e-05	0.000299	CcSEcCtD
Darifenacin—Gastrointestinal pain—Capecitabine—breast cancer	4.54e-05	0.000297	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—breast cancer	4.54e-05	0.000297	CcSEcCtD
Darifenacin—Abdominal pain—Docetaxel—breast cancer	4.54e-05	0.000296	CcSEcCtD
Darifenacin—Dizziness—Paclitaxel—breast cancer	4.48e-05	0.000292	CcSEcCtD
Darifenacin—Vision blurred—Epirubicin—breast cancer	4.47e-05	0.000292	CcSEcCtD
Darifenacin—Cough—Methotrexate—breast cancer	4.42e-05	0.000289	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—breast cancer	4.42e-05	0.000288	CcSEcCtD
Darifenacin—Abdominal pain—Capecitabine—breast cancer	4.39e-05	0.000287	CcSEcCtD
Darifenacin—Methadone—CYP3A4—breast cancer	4.39e-05	0.015	CrCbGaD
Darifenacin—Flatulence—Doxorubicin—breast cancer	4.33e-05	0.000282	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—breast cancer	4.32e-05	0.000282	CcSEcCtD
Darifenacin—Vomiting—Paclitaxel—breast cancer	4.31e-05	0.000281	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—breast cancer	4.3e-05	0.000281	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.29e-05	0.00028	CcSEcCtD
Darifenacin—Rash—Paclitaxel—breast cancer	4.27e-05	0.000279	CcSEcCtD
Darifenacin—Dermatitis—Paclitaxel—breast cancer	4.27e-05	0.000279	CcSEcCtD
Darifenacin—Syncope—Epirubicin—breast cancer	4.25e-05	0.000278	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—breast cancer	4.25e-05	0.000277	CcSEcCtD
Darifenacin—Headache—Paclitaxel—breast cancer	4.24e-05	0.000277	CcSEcCtD
Darifenacin—Hypersensitivity—Docetaxel—breast cancer	4.23e-05	0.000276	CcSEcCtD
Darifenacin—Palpitations—Epirubicin—breast cancer	4.19e-05	0.000274	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—breast cancer	4.17e-05	0.000272	CcSEcCtD
Darifenacin—Loss of consciousness—Epirubicin—breast cancer	4.17e-05	0.000272	CcSEcCtD
Darifenacin—Cough—Epirubicin—breast cancer	4.14e-05	0.00027	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—breast cancer	4.14e-05	0.00027	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—breast cancer	4.14e-05	0.00027	CcSEcCtD
Darifenacin—Asthenia—Docetaxel—breast cancer	4.12e-05	0.000269	CcSEcCtD
Darifenacin—Infection—Methotrexate—breast cancer	4.11e-05	0.000268	CcSEcCtD
Darifenacin—Hypertension—Epirubicin—breast cancer	4.1e-05	0.000267	CcSEcCtD
Darifenacin—Hypersensitivity—Capecitabine—breast cancer	4.09e-05	0.000267	CcSEcCtD
Darifenacin—Pruritus—Docetaxel—breast cancer	4.06e-05	0.000265	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—breast cancer	4.06e-05	0.000265	CcSEcCtD
Darifenacin—Arthralgia—Epirubicin—breast cancer	4.04e-05	0.000264	CcSEcCtD
Darifenacin—Nausea—Paclitaxel—breast cancer	4.02e-05	0.000263	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—breast cancer	4.02e-05	0.000262	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	4.01e-05	0.000262	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—breast cancer	4e-05	0.000261	CcSEcCtD
Darifenacin—Asthenia—Capecitabine—breast cancer	3.99e-05	0.00026	CcSEcCtD
Darifenacin—Dry mouth—Epirubicin—breast cancer	3.95e-05	0.000258	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—breast cancer	3.94e-05	0.000257	CcSEcCtD
Darifenacin—Pruritus—Capecitabine—breast cancer	3.93e-05	0.000257	CcSEcCtD
Darifenacin—Diarrhoea—Docetaxel—breast cancer	3.93e-05	0.000256	CcSEcCtD
Darifenacin—Confusional state—Epirubicin—breast cancer	3.9e-05	0.000255	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—breast cancer	3.88e-05	0.000253	CcSEcCtD
Darifenacin—Anaphylactic shock—Epirubicin—breast cancer	3.87e-05	0.000253	CcSEcCtD
Darifenacin—Oedema—Epirubicin—breast cancer	3.87e-05	0.000253	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—breast cancer	3.86e-05	0.000252	CcSEcCtD
Darifenacin—Infection—Epirubicin—breast cancer	3.85e-05	0.000251	CcSEcCtD
Darifenacin—Cough—Doxorubicin—breast cancer	3.83e-05	0.00025	CcSEcCtD
Darifenacin—Shock—Epirubicin—breast cancer	3.81e-05	0.000249	CcSEcCtD
Darifenacin—Diarrhoea—Capecitabine—breast cancer	3.8e-05	0.000248	CcSEcCtD
Darifenacin—Nervous system disorder—Epirubicin—breast cancer	3.8e-05	0.000248	CcSEcCtD
Darifenacin—Dizziness—Docetaxel—breast cancer	3.8e-05	0.000248	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—breast cancer	3.79e-05	0.000247	CcSEcCtD
Darifenacin—Tachycardia—Epirubicin—breast cancer	3.78e-05	0.000247	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—breast cancer	3.77e-05	0.000246	CcSEcCtD
Darifenacin—Skin disorder—Epirubicin—breast cancer	3.76e-05	0.000246	CcSEcCtD
Darifenacin—Hyperhidrosis—Epirubicin—breast cancer	3.74e-05	0.000244	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—breast cancer	3.74e-05	0.000244	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—breast cancer	3.74e-05	0.000244	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.71e-05	0.000242	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—breast cancer	3.69e-05	0.000241	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—breast cancer	3.68e-05	0.00024	CcSEcCtD
Darifenacin—Dizziness—Capecitabine—breast cancer	3.68e-05	0.00024	CcSEcCtD
Darifenacin—Dry mouth—Doxorubicin—breast cancer	3.65e-05	0.000239	CcSEcCtD
Darifenacin—Methadone—ABCB1—breast cancer	3.65e-05	0.0125	CrCbGaD
Darifenacin—Vomiting—Docetaxel—breast cancer	3.65e-05	0.000238	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—breast cancer	3.64e-05	0.000238	CcSEcCtD
Darifenacin—Rash—Docetaxel—breast cancer	3.62e-05	0.000236	CcSEcCtD
Darifenacin—Dermatitis—Docetaxel—breast cancer	3.62e-05	0.000236	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—breast cancer	3.61e-05	0.000236	CcSEcCtD
Darifenacin—Headache—Docetaxel—breast cancer	3.6e-05	0.000235	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—breast cancer	3.58e-05	0.000234	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—breast cancer	3.58e-05	0.000234	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—breast cancer	3.57e-05	0.000233	CcSEcCtD
Darifenacin—Infection—Doxorubicin—breast cancer	3.56e-05	0.000232	CcSEcCtD
Darifenacin—Pain—Methotrexate—breast cancer	3.54e-05	0.000231	CcSEcCtD
Darifenacin—Vomiting—Capecitabine—breast cancer	3.53e-05	0.000231	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Epirubicin—breast cancer	3.53e-05	0.00023	CcSEcCtD
Darifenacin—Shock—Doxorubicin—breast cancer	3.52e-05	0.00023	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—breast cancer	3.51e-05	0.000229	CcSEcCtD
Darifenacin—Rash—Capecitabine—breast cancer	3.5e-05	0.000229	CcSEcCtD
Darifenacin—Insomnia—Epirubicin—breast cancer	3.5e-05	0.000229	CcSEcCtD
Darifenacin—Dermatitis—Capecitabine—breast cancer	3.5e-05	0.000229	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—breast cancer	3.5e-05	0.000228	CcSEcCtD
Darifenacin—Headache—Capecitabine—breast cancer	3.48e-05	0.000227	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—breast cancer	3.48e-05	0.000227	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—breast cancer	3.46e-05	0.000226	CcSEcCtD
Darifenacin—Dyspnoea—Epirubicin—breast cancer	3.45e-05	0.000225	CcSEcCtD
Darifenacin—Somnolence—Epirubicin—breast cancer	3.44e-05	0.000225	CcSEcCtD
Darifenacin—Nausea—Docetaxel—breast cancer	3.41e-05	0.000223	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—breast cancer	3.41e-05	0.000223	CcSEcCtD
Darifenacin—Dyspepsia—Epirubicin—breast cancer	3.41e-05	0.000223	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—breast cancer	3.38e-05	0.000221	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Epirubicin—breast cancer	3.34e-05	0.000218	CcSEcCtD
Darifenacin—Pain—Epirubicin—breast cancer	3.31e-05	0.000216	CcSEcCtD
Darifenacin—Constipation—Epirubicin—breast cancer	3.31e-05	0.000216	CcSEcCtD
Darifenacin—Nausea—Capecitabine—breast cancer	3.3e-05	0.000216	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—breast cancer	3.27e-05	0.000214	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.26e-05	0.000213	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—breast cancer	3.24e-05	0.000212	CcSEcCtD
Darifenacin—Dyspnoea—Doxorubicin—breast cancer	3.19e-05	0.000209	CcSEcCtD
Darifenacin—Feeling abnormal—Epirubicin—breast cancer	3.19e-05	0.000208	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—breast cancer	3.18e-05	0.000208	CcSEcCtD
Darifenacin—Gastrointestinal pain—Epirubicin—breast cancer	3.17e-05	0.000207	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—breast cancer	3.15e-05	0.000206	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—breast cancer	3.09e-05	0.000202	CcSEcCtD
Darifenacin—Pain—Doxorubicin—breast cancer	3.06e-05	0.0002	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—breast cancer	3.06e-05	0.0002	CcSEcCtD
Darifenacin—Abdominal pain—Epirubicin—breast cancer	3.06e-05	0.0002	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—breast cancer	3.05e-05	0.000199	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—breast cancer	2.97e-05	0.000194	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—breast cancer	2.95e-05	0.000193	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—breast cancer	2.93e-05	0.000191	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—breast cancer	2.93e-05	0.000191	CcSEcCtD
Darifenacin—Hypersensitivity—Epirubicin—breast cancer	2.85e-05	0.000186	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—breast cancer	2.83e-05	0.000185	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—breast cancer	2.83e-05	0.000185	CcSEcCtD
Darifenacin—Asthenia—Epirubicin—breast cancer	2.78e-05	0.000181	CcSEcCtD
Darifenacin—Pruritus—Epirubicin—breast cancer	2.74e-05	0.000179	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—breast cancer	2.74e-05	0.000179	CcSEcCtD
Darifenacin—Diarrhoea—Epirubicin—breast cancer	2.65e-05	0.000173	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—breast cancer	2.64e-05	0.000172	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—breast cancer	2.63e-05	0.000172	CcSEcCtD
Darifenacin—Rash—Methotrexate—breast cancer	2.61e-05	0.00017	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—breast cancer	2.61e-05	0.00017	CcSEcCtD
Darifenacin—Headache—Methotrexate—breast cancer	2.59e-05	0.000169	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—breast cancer	2.57e-05	0.000168	CcSEcCtD
Darifenacin—Dizziness—Epirubicin—breast cancer	2.56e-05	0.000167	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—breast cancer	2.53e-05	0.000165	CcSEcCtD
Darifenacin—Vomiting—Epirubicin—breast cancer	2.46e-05	0.000161	CcSEcCtD
Darifenacin—Nausea—Methotrexate—breast cancer	2.46e-05	0.00016	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—breast cancer	2.45e-05	0.00016	CcSEcCtD
Darifenacin—Rash—Epirubicin—breast cancer	2.44e-05	0.000159	CcSEcCtD
Darifenacin—Dermatitis—Epirubicin—breast cancer	2.44e-05	0.000159	CcSEcCtD
Darifenacin—Headache—Epirubicin—breast cancer	2.43e-05	0.000158	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—breast cancer	2.37e-05	0.000155	CcSEcCtD
Darifenacin—Nausea—Epirubicin—breast cancer	2.3e-05	0.00015	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—breast cancer	2.28e-05	0.000149	CcSEcCtD
Darifenacin—Rash—Doxorubicin—breast cancer	2.26e-05	0.000147	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—breast cancer	2.26e-05	0.000147	CcSEcCtD
Darifenacin—Headache—Doxorubicin—breast cancer	2.24e-05	0.000147	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—breast cancer	2.13e-05	0.000139	CcSEcCtD
Darifenacin—CHRM5—Signaling Pathways—IL2—breast cancer	3.34e-06	7.15e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APC—breast cancer	3.33e-06	7.13e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CG—breast cancer	3.33e-06	7.13e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KIT—breast cancer	3.33e-06	7.13e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—breast cancer	3.32e-06	7.11e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—NOS3—breast cancer	3.31e-06	7.08e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ABCB1—breast cancer	3.3e-06	7.07e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGF—breast cancer	3.3e-06	7.07e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—breast cancer	3.3e-06	7.06e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CG—breast cancer	3.3e-06	7.06e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APC—breast cancer	3.3e-06	7.06e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KIT—breast cancer	3.3e-06	7.06e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ACHE—breast cancer	3.29e-06	7.05e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTT1—breast cancer	3.29e-06	7.05e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGF—breast cancer	3.29e-06	7.05e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CDKN1A—breast cancer	3.29e-06	7.04e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PTEN—breast cancer	3.28e-06	7.02e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGF—breast cancer	3.26e-06	6.98e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCND1—breast cancer	3.25e-06	6.97e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—JUN—breast cancer	3.25e-06	6.95e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—TYMS—breast cancer	3.24e-06	6.94e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CTNNB1—breast cancer	3.22e-06	6.9e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK8—breast cancer	3.21e-06	6.87e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PLA2G4A—breast cancer	3.21e-06	6.86e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTM1—breast cancer	3.21e-06	6.86e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NCOR1—breast cancer	3.21e-06	6.86e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AKT1—breast cancer	3.2e-06	6.85e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—MAPK3—breast cancer	3.2e-06	6.85e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—MAPK3—breast cancer	3.19e-06	6.83e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—breast cancer	3.16e-06	6.76e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—MAPK3—breast cancer	3.16e-06	6.76e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1A—breast cancer	3.15e-06	6.74e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PTEN—breast cancer	3.14e-06	6.72e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—BRAF—breast cancer	3.14e-06	6.72e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—BRAF—breast cancer	3.13e-06	6.7e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP17A1—breast cancer	3.12e-06	6.67e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—BRAF—breast cancer	3.1e-06	6.64e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ENO1—breast cancer	3.08e-06	6.6e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS1—breast cancer	3.08e-06	6.6e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK8—breast cancer	3.07e-06	6.58e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GPX1—breast cancer	3.07e-06	6.57e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AKT1—breast cancer	3.06e-06	6.56e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IGF1—breast cancer	3.06e-06	6.55e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT2—breast cancer	3.06e-06	6.54e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CB—breast cancer	3.05e-06	6.53e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IGF1—breast cancer	3.05e-06	6.53e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT2—breast cancer	3.05e-06	6.52e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—breast cancer	3.04e-06	6.52e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SRC—breast cancer	3.04e-06	6.51e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP1A1—breast cancer	3.04e-06	6.51e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—breast cancer	3.03e-06	6.49e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP2D6—breast cancer	3.02e-06	6.48e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS2—breast cancer	3.02e-06	6.47e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IGF1—breast cancer	3.02e-06	6.46e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT2—breast cancer	3.02e-06	6.46e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ERCC2—breast cancer	3.01e-06	6.45e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—breast cancer	3e-06	6.43e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NCOA2—breast cancer	2.97e-06	6.36e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—breast cancer	2.96e-06	6.34e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CD—breast cancer	2.94e-06	6.29e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—STAT3—breast cancer	2.93e-06	6.28e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CD—breast cancer	2.93e-06	6.27e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SRC—breast cancer	2.91e-06	6.24e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	2.91e-06	6.23e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SERPINE1—breast cancer	2.9e-06	6.22e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	2.9e-06	6.21e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CD—breast cancer	2.9e-06	6.21e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SERPINE1—breast cancer	2.9e-06	6.2e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—FASN—breast cancer	2.88e-06	6.16e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—KRAS—breast cancer	2.88e-06	6.15e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	2.87e-06	6.15e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—BCHE—breast cancer	2.87e-06	6.14e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SERPINE1—breast cancer	2.87e-06	6.14e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—KRAS—breast cancer	2.87e-06	6.14e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—KRAS—breast cancer	2.84e-06	6.08e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—breast cancer	2.84e-06	6.07e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—MTHFR—breast cancer	2.83e-06	6.07e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC5A5—breast cancer	2.83e-06	6.06e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—STAT3—breast cancer	2.81e-06	6.01e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MAPK3—breast cancer	2.8e-06	6e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOS3—breast cancer	2.77e-06	5.94e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOS3—breast cancer	2.76e-06	5.92e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOS3—breast cancer	2.74e-06	5.86e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NQO1—breast cancer	2.74e-06	5.86e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC2A1—breast cancer	2.74e-06	5.86e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MYC—breast cancer	2.73e-06	5.84e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFB1—breast cancer	2.72e-06	5.82e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MAPK3—breast cancer	2.68e-06	5.75e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—breast cancer	2.67e-06	5.71e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	2.64e-06	5.65e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTEN—breast cancer	2.64e-06	5.64e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	2.63e-06	5.64e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MDM2—breast cancer	2.63e-06	5.63e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1B1—breast cancer	2.62e-06	5.61e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MDM2—breast cancer	2.62e-06	5.61e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RAF1—breast cancer	2.62e-06	5.61e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CAV1—breast cancer	2.61e-06	5.6e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RAF1—breast cancer	2.61e-06	5.59e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MYC—breast cancer	2.61e-06	5.59e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RELA—breast cancer	2.61e-06	5.59e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	2.61e-06	5.58e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFB1—breast cancer	2.6e-06	5.57e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RELA—breast cancer	2.6e-06	5.57e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MDM2—breast cancer	2.6e-06	5.56e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ERBB2—breast cancer	2.59e-06	5.55e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RAF1—breast cancer	2.59e-06	5.54e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ERBB2—breast cancer	2.59e-06	5.53e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RELA—breast cancer	2.58e-06	5.52e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.57e-06	5.51e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ERBB2—breast cancer	2.56e-06	5.48e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MTOR—breast cancer	2.56e-06	5.48e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CB—breast cancer	2.56e-06	5.48e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—breast cancer	2.55e-06	5.47e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MTOR—breast cancer	2.55e-06	5.46e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CB—breast cancer	2.55e-06	5.46e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MTOR—breast cancer	2.53e-06	5.41e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CB—breast cancer	2.53e-06	5.41e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KRAS—breast cancer	2.52e-06	5.39e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NCOA1—breast cancer	2.5e-06	5.36e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP19A1—breast cancer	2.47e-06	5.28e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—STK11—breast cancer	2.47e-06	5.28e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL8—breast cancer	2.46e-06	5.27e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL8—breast cancer	2.45e-06	5.25e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—HRAS—breast cancer	2.44e-06	5.23e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—HRAS—breast cancer	2.44e-06	5.21e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL8—breast cancer	2.43e-06	5.2e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—HRAS—breast cancer	2.41e-06	5.16e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KRAS—breast cancer	2.41e-06	5.16e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1B—breast cancer	2.4e-06	5.14e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1B—breast cancer	2.39e-06	5.13e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CG—breast cancer	2.38e-06	5.1e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AKT1—breast cancer	2.38e-06	5.09e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1B—breast cancer	2.37e-06	5.08e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AKT1—breast cancer	2.37e-06	5.07e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CASP3—breast cancer	2.35e-06	5.04e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL2—breast cancer	2.35e-06	5.03e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CASP3—breast cancer	2.35e-06	5.02e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AKT1—breast cancer	2.35e-06	5.02e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL2—breast cancer	2.34e-06	5.02e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—breast cancer	2.34e-06	5.01e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—breast cancer	2.33e-06	4.99e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CASP3—breast cancer	2.32e-06	4.97e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL2—breast cancer	2.32e-06	4.97e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CA—breast cancer	2.31e-06	4.95e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—breast cancer	2.31e-06	4.94e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—COMT—breast cancer	2.29e-06	4.91e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCND1—breast cancer	2.29e-06	4.91e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—JUN—breast cancer	2.29e-06	4.9e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCND1—breast cancer	2.28e-06	4.89e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTP1—breast cancer	2.28e-06	4.88e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—JUN—breast cancer	2.28e-06	4.88e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CTNNB1—breast cancer	2.27e-06	4.86e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CTNNB1—breast cancer	2.26e-06	4.84e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCND1—breast cancer	2.26e-06	4.84e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—JUN—breast cancer	2.26e-06	4.83e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HMOX1—breast cancer	2.25e-06	4.82e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ITPR1—breast cancer	2.24e-06	4.81e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CTNNB1—breast cancer	2.24e-06	4.8e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—breast cancer	2.24e-06	4.79e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—breast cancer	2.22e-06	4.76e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—breast cancer	2.22e-06	4.75e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1A—breast cancer	2.22e-06	4.75e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CA—breast cancer	2.22e-06	4.74e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PTEN—breast cancer	2.21e-06	4.73e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1A—breast cancer	2.21e-06	4.73e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PTEN—breast cancer	2.2e-06	4.72e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—breast cancer	2.2e-06	4.7e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1A—breast cancer	2.19e-06	4.68e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PTEN—breast cancer	2.18e-06	4.67e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK8—breast cancer	2.16e-06	4.63e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCB1—breast cancer	2.16e-06	4.62e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AKT1—breast cancer	2.16e-06	4.62e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK8—breast cancer	2.16e-06	4.62e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AKT1—breast cancer	2.15e-06	4.6e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—breast cancer	2.14e-06	4.59e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HRAS—breast cancer	2.14e-06	4.58e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK8—breast cancer	2.14e-06	4.57e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AKT1—breast cancer	2.13e-06	4.56e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—TYMS—breast cancer	2.12e-06	4.54e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NCOR1—breast cancer	2.1e-06	4.49e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.1e-06	4.49e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTM1—breast cancer	2.1e-06	4.49e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CD—breast cancer	2.09e-06	4.48e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—breast cancer	2.07e-06	4.42e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SRC—breast cancer	2.05e-06	4.39e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HRAS—breast cancer	2.05e-06	4.39e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—breast cancer	2.05e-06	4.39e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SRC—breast cancer	2.04e-06	4.38e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SRC—breast cancer	2.02e-06	4.33e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GPX1—breast cancer	2.01e-06	4.3e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—breast cancer	2e-06	4.28e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—breast cancer	1.99e-06	4.26e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1A1—breast cancer	1.99e-06	4.25e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—STAT3—breast cancer	1.98e-06	4.23e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NOS3—breast cancer	1.98e-06	4.23e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—breast cancer	1.97e-06	4.22e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—STAT3—breast cancer	1.97e-06	4.22e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ERCC2—breast cancer	1.97e-06	4.22e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—breast cancer	1.96e-06	4.2e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—STAT3—breast cancer	1.95e-06	4.18e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT1—breast cancer	1.89e-06	4.05e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MAPK3—breast cancer	1.89e-06	4.05e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MAPK3—breast cancer	1.88e-06	4.03e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MAPK3—breast cancer	1.87e-06	3.99e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CA—breast cancer	1.86e-06	3.98e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—MTHFR—breast cancer	1.85e-06	3.97e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MYC—breast cancer	1.84e-06	3.93e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFB1—breast cancer	1.83e-06	3.93e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MYC—breast cancer	1.83e-06	3.92e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFB1—breast cancer	1.83e-06	3.91e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CB—breast cancer	1.82e-06	3.91e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MYC—breast cancer	1.81e-06	3.88e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT1—breast cancer	1.81e-06	3.88e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFB1—breast cancer	1.81e-06	3.87e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS2—breast cancer	1.81e-06	3.87e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—breast cancer	1.8e-06	3.85e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—breast cancer	1.79e-06	3.84e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—breast cancer	1.77e-06	3.8e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CAV1—breast cancer	1.71e-06	3.66e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KRAS—breast cancer	1.7e-06	3.64e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KRAS—breast cancer	1.69e-06	3.62e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KRAS—breast cancer	1.68e-06	3.59e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTEN—breast cancer	1.58e-06	3.38e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CA—breast cancer	1.56e-06	3.34e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CG—breast cancer	1.56e-06	3.33e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CA—breast cancer	1.56e-06	3.33e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CA—breast cancer	1.54e-06	3.3e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AKT1—breast cancer	1.52e-06	3.25e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—breast cancer	1.51e-06	3.23e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—breast cancer	1.5e-06	3.22e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—breast cancer	1.49e-06	3.19e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HRAS—breast cancer	1.44e-06	3.09e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HRAS—breast cancer	1.44e-06	3.08e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HRAS—breast cancer	1.43e-06	3.05e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—breast cancer	1.38e-06	2.96e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—breast cancer	1.38e-06	2.95e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CD—breast cancer	1.37e-06	2.93e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—breast cancer	1.36e-06	2.92e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—breast cancer	1.35e-06	2.89e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NOS3—breast cancer	1.29e-06	2.77e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT1—breast cancer	1.27e-06	2.73e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT1—breast cancer	1.27e-06	2.72e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT1—breast cancer	1.26e-06	2.69e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CB—breast cancer	1.19e-06	2.55e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS2—breast cancer	1.18e-06	2.53e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CA—breast cancer	1.11e-06	2.38e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTEN—breast cancer	1.03e-06	2.21e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AKT1—breast cancer	9.09e-07	1.95e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CA—breast cancer	7.27e-07	1.56e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AKT1—breast cancer	5.94e-07	1.27e-05	CbGpPWpGaD
